eligibility_summary
Eligible: adults (>18) with RR myeloma after ≥3 lines (IMiD, PI, anti‑CD38), no CNS disease, ECOG ≤2, measurable MM (M‑protein/FLC or ≥30% BM PCs), ≥2 wks from last therapy, labs: bili ≤1.5, AST/ALT ≤2.5×ULN, Cr <2, EF >45%, O2 ≥92%, consent, contraception. Exclude: ASCT <6 wks, allo‑HCT/GVHD, investigational <28 d, serious CV disease, active IV infection, HIV or hep B/C PCR+, pregnant/lactating, other malignancy needing therapy, autoimmune disease needing immunosuppression.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
NCT05546723: Phase 1, open-label, 3+3 dose-escalation study of LMY-920, an autologous ligand-based CAR-T cell therapy for relapsed/refractory multiple myeloma. Intervention: Patient T cells engineered to express a CAR that uses the BAFF (BLyS) ligand as the binding domain, enabling multi-antigen recognition of the BAFF-receptor family—BAFF-R (BR3), BCMA, and TACI. Mechanism: Antigen engagement activates CAR-T cells to proliferate and deliver targeted cytotoxicity and cytokine-mediated killing of malignant plasma cells, aiming to overcome antigen escape after prior BCMA-directed therapies. Targets/pathways: Myeloma and late B-lineage cells expressing BAFF-R/BCMA/TACI, BAFF/BLyS–TNFR superfamily signaling. Primary goal: determine MTD and RP2D.